1. Patients with newly diagnosed stage IV ovarian cancer or first-recurrent ovarian cancer, aged \>18 years.
2. No clinically significant abnormalities in complete blood count, liver function, or renal function.
3. Estimated life expectancy ≥6 months.
4. At least one measurable target lesion per RECIST version 1.1.
5. Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days prior to the start of the study procedures; patients with reproductive potential must agree to use effective contraception to avoid pregnancy during the study and within 3 months after the last imaging examination.
6. Female patients must adopt effective contraceptive measures throughout the study period and for 6 months after study completion.
7. Patients must fully understand and voluntarily participate in the trial, and provide written informed consent.
You may not be if
1. Severe hepatic or renal dysfunction.
2. Women who are planning pregnancy, pregnant, or breastfeeding.
3. Inability to remain supine for 30 minutes.
4. Inability to provide informed consent.
5. Claustrophobia or other psychiatric disorders.
6. Known allergy to the investigational drug or its excipients.
7. Any other condition that the investigator deems unsuitable for participation in the trial.
